Tiziana Life Sciences : Extension of At the Market Sales Agreement

Tiziana Life Sciences plc (AIM:TILS) is pleased to announce the agreement of an extension to the current At the Market Sales Agreement with ThinkEquity, a division of Fordham Financial Management, Inc.

As previously announced on 15 April 2020, Tiziana Life Sciences plc (the 'Company'), entered into an ATM Sales Agreement (the 'Offering Agreement') with ThinkEquity, a division of Fordham Financial Management, Inc., as sales agent ('ThinkEquity'), pursuant to which the Company may offer and sell, from time to time through ThinkEquity American Depositary ADSs, each representing five (5) ordinary shares of nominal value £0.03 (the 'ADSs'), having an aggregate offering price of up to $20 million.

The offering of ADSs pursuant to the Offering Agreement continues to run and will now terminate upon the earlier of: (a) the sale of all of the ADSs subject to the Offering Agreement; (b) the termination of the Offering Agreement by ThinkEquity or the Company, as permitted in accordance with its terms; or (c) 31 July 2020, unless extended.

Enquiries:

Gabriele Cerrone, Chairman and founder [phone]

Cairn Financial Advisers LLP (Nominated adviser)

Liam Murray / Jo Turner + 44 (0)20 7213 0883

Optiva Securities Limited

Robert Emmet + 44 (0)20 3981 4173

For further information, please visit the Company's website at www.tizianalifesciences.com.